Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men ≥ 30 years of age with non-metastatic prostate cancer, having undergone bilateral orchiectomy or initiated androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists and is expected to continue on ADT for at least 12 months~* Adequate visual accuracy allowing eye testing~* Bone Mineral Density (BMD) requirements: Osteopenia if under 70 years of age; Osteopenia or normal BMD if over 70 years of age~* Signed informed consent~Exclusion Criteria:~* Previous surgery for cataracts in both eyes, current diagnosis of cataracts, cataracts surgery foreseen in the near future, or ocular disease leading to visual loss~* Diagnosis of osteoporosis

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered by subcutaneous injection on Day 1 and at Month 6.
- Denosumab (Type: EXPERIMENTAL): Participants received denosumab 60 mg administered by subcutaneous injection on Day 1 and at Month 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).